Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1999 Oct;83(10):1186–1189. doi: 10.1136/bjo.83.10.1186

Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease

F Verbraak 1, R Boom 1, P Dillen 1, G J van den Horn 1, A Kijlstra 1, M D de Smet 1
PMCID: PMC1722831  PMID: 10502584

Abstract

BACKGROUND/AIMS—In the pre-HAART era, HIV positive patients with CD4+ cell counts below 50 cells ×106/l, and those with detectable cytomegalovirus (CMV) DNA in their peripheral blood, were considered to be at high risk for the development of CMV disease. With the start of highly active antiretroviral therapy (HAART), a restoration of immune function occurred in these patients, and as a consequence patients became less vulnerable to CMV disease. Since it is not exactly known how HAART influences CMV viral load in peripheral blood and the incidence of CMV disease in high risk HIV positive patients a group of patients was followed before and after initiation of HAART.
METHODS—29 HIV positive patients, seen in the first 3 months of 1996 at the AIDS clinic of the Academic Medical Centre, at high risk for development of CMV disease (positive CMV DNA assay in blood and/or CD4+ cell count below 50 cells ×106/l), not receiving anti-CMV maintenance therapy, were included in a prospective cohort study. HAART was started in the second trimester of 1996. Patients were evaluated for the occurrence of CMV retinitis, or CMV disease elsewhere, comparing the incidence of CMV events before and after the start of HAART. Following the introduction of HAART, CD4+ cell counts and quantitative polymerase chain reaction (PCR) for CMV DNA in blood were monitored in all patients who remained alive and were not receiving anti-CMV maintenance therapy (n=22). Follow up was performed until August 1998; the mean follow up after the start of HAART was 14.9 months (range 8-22 months).
RESULTS—In the pre-HAART period four patients developed CMV disease, and four died (without clinically manifest CMV disease). After the start of HAART no patient developed CMV disease or died. With HAART, the mean CD4+ cell counts increased from 34 cells ×106/l to 194 cells ×106/l at the end of follow up. CMV DNA could be detected in the blood of 11 patients. Quantification showed a decline in the amount of detectable DNA during follow up. At the last examination only one patient showed a positive PCR assay. This was the only patient with a CD4+ cell count remaining below 100 cells ×106/l.
CONCLUSION—In HIV positive patients at high risk of CMV retinitis, either with a positive CMV PCR assay in blood and/or with CD4+ cell counts below 50 cell ×106/l, HAART causes a dramatic decrease in the occurrence of CMV disease. This decrease is paralleled by an increase in CD4+ cell count, and a decrease in the amount of CMV DNA in the blood, which was below detection levels in all patients with CD4+ cell counts above 100 cells ×106/l.



Full Text

The Full Text of this article is available as a PDF (72.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ash S. Combination HIV therapy and opportunistic infections of the eye in people with AIDS. Br J Ophthalmol. 1998 Sep;82(9):981–982. doi: 10.1136/bjo.82.9.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boom R., Sol C. J., Salimans M. M., Jansen C. L., Wertheim-van Dillen P. M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990 Mar;28(3):495–503. doi: 10.1128/jcm.28.3.495-503.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bowen E. F., Sabin C. A., Wilson P., Griffiths P. D., Davey C. C., Johnson M. A., Emery V. C. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 1997 Jun;11(7):889–893. doi: 10.1097/00002030-199707000-00008. [DOI] [PubMed] [Google Scholar]
  4. Dodt K. K., Jacobsen P. H., Hofmann B., Meyer C., Kolmos H. J., Skinhøj P., Norrild B., Mathiesen L. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS. 1997 Mar;11(3):F21–F28. doi: 10.1097/00002030-199703110-00001. [DOI] [PubMed] [Google Scholar]
  5. Jacobson M. A., Zegans M., Pavan P. R., O'Donnell J. J., Sattler F., Rao N., Owens S., Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997 May 17;349(9063):1443–1445. doi: 10.1016/S0140-6736(96)11431-8. [DOI] [PubMed] [Google Scholar]
  6. Laue T., Mertenskötter T., Grewing T., Degen O., van Lunzen J., Dietrich M., Schmitz H. Clinical significance of qualitative human cytomegalovirus (HCMV) detection in cell-free serum samples in HIV-infected patients at risk for HCMV disease. AIDS. 1997 Jul 15;11(9):1195–1196. doi: 10.1097/00002030-199709000-00023. [DOI] [PubMed] [Google Scholar]
  7. Mallolas J., Arrizabalaga J., Loncá M., Gatell J. M., Adán A., Martínez-Chamorro E., Tortajada C., Rodríguez-Arrondo F., Blanco A., Guelar A. Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors. AIDS. 1997 Nov 15;11(14):1785–1787. [PubMed] [Google Scholar]
  8. Rasmussen L., Zipeto D., Wolitz R. A., Dowling A., Efron B., Merigan T. C. Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. J Infect Dis. 1997 Nov;176(5):1146–1155. doi: 10.1086/514106. [DOI] [PubMed] [Google Scholar]
  9. Shinkai M., Bozzette S. A., Powderly W., Frame P., Spector S. A. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis. 1997 Feb;175(2):302–308. doi: 10.1093/infdis/175.2.302. [DOI] [PubMed] [Google Scholar]
  10. Spector S. A., Wong R., Hsia K., Pilcher M., Stempien M. J. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest. 1998 Jan 15;101(2):497–502. doi: 10.1172/JCI1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Verbraak F. D., van den Horn G. J., van der Meer J. T., Paydafar D., ten Kate F. J., Wertheim-van Dillen P. M., Kijlstra A. Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients. Br J Ophthalmol. 1998 Jul;82(7):748–750. doi: 10.1136/bjo.82.7.748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Walsh J. C., Jones C. D., Barnes E. A., Gazzard B. G., Mitchell S. M. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS. 1998 Apr 16;12(6):613–618. doi: 10.1097/00002030-199806000-00010. [DOI] [PubMed] [Google Scholar]
  13. van den Horn G. J., Meenken C., Danner S. A., Reiss P., de Smet M. D. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol. 1998 Sep;82(9):988–990. doi: 10.1136/bjo.82.9.988. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES